Skip to main content

Coronary Atherosclerosis in Masters Athletes: Mechanisms and Implications for Cardiovascular Disease Risk

Current Treatment Options in Cardiovascular Medicine volume 21, Article number: 87 (2019) Cite this article

Abstract

Purpose of review

This manuscript reviews the data on the mechanisms and significance of atherosclerotic cardiovascular disease (ASCVD) in masters athletes. It describes recent advances in understanding the biological pathway for the development and progression of ASCVD in athletes. It also reviews salient clinical trials, guidelines on managing ASCVD in masters athletes, and future research directions.

Recent findings

Recent data have produced controversy as to whether high levels of physical activity and endurance training can promote ASCVD. Longstanding, vigorous endurance exercise may increase the development of calcified and non-calcified coronary plaques. There are no clinical trials to inform clinicians on how to manage masters athletes with occult ASCVD. We provide a review of the data on ASCVD in older athletes, the risks and benefits of exercise in active individuals with ASCVD, and our approach to evaluating and managing these patients.

Summary

Vigorous physical exertion transiently increases the risk of acute coronary syndrome (ACS) and sudden cardiac death in patients with ASCVD. New research has demonstrated increases in both calcified and non-calcified plaque in athletes, although the dominant plaque type is usually calcific. The mechanisms mediating this possible increase in atherosclerosis in active individuals is uncertain, as is the prognostic implications of the increased atherosclerosis. The predominance of calcified plaque may indicate that coronary plaques in athletes are less prone to rupture and to produce acute coronary events. Some guidelines offer recommendations on the management of non-athletic patients with elevated CAC but data on athletes is scarce. Until additional studies are available, we suggest that athletes with CAC values > 100 Agatston units be managed as if they have preclinical ASCVD. They should be informed of the symptoms of angina and ACS and the importance of prompt medical attention should such symptoms occur. Serum calcium and parathyroid hormones levels should be measured to exclude hyperparathyroidism. Patients should undergo symptom-limited maximal exercise stress testing and aggressive lipid treatment to achieve low-density lipoprotein cholesterol (LDL-C) values < 70 mg/dl.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Favaloro R. A revival of Paul Dudley White: an overview of present medical practice and of our society. Circulation. 1999;99(12):1525–37.

    CAS  Article  Google Scholar 

  2. Currens JH, White PD. Half a century of running. clinical, physiologic and autopsy findings in the case of Clarence DeMar (“Mr. Marathon”). N Engl J Med. 1961 Nov 16;265:988–93.

    CAS  Article  Google Scholar 

  3. Running USA. http://www.runningusaorg/statistics. Accessed November 5, 2016.

  4. • Thompson PD, Myerburg RJ, Levine BD, Udelson JE, Kovacs RJ. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task Force 8: coronary artery disease: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2015;66(21):2406–11. The 2015 ACC guidelines on the management of ASCVD in competitive athletes.

    Article  Google Scholar 

  5. Borjesson M, Dellborg M, Niebauer J, LaGerche A, Schmied C, Solberg EE, et al. Recommendations for participation in leisure time or competitive sports in athletes-patients with coronary artery disease: a position statement from the Sports Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2019 Jan 1;40(1):13–8.

    Article  Google Scholar 

  6. Marijon E, Tafflet M, Celermajer DS, Dumas F, Perier MC, Mustafic H, et al. Sports-related sudden death in the general population. Circulation. 2011 Aug 9;124(6):672–81.

    Article  Google Scholar 

  7. Giri S, Thompson PD, Kiernan FJ, Clive J, Fram DB, Mitchel JF, et al. Clinical and angiographic characteristics of exertion-related acute myocardial infarction. Jama. 1999 Nov 10;282(18):1731–6.

    CAS  Article  Google Scholar 

  8. Siscovick DS, Weiss NS, Fletcher RH, Lasky T. The incidence of primary cardiac arrest during vigorous exercise. N Engl J Med. 1984;311(14):874–7.

    CAS  Article  Google Scholar 

  9. Parker MW, Thompson PD. Assessment and management of atherosclerosis in the athletic patient. Prog Cardiovasc Dis. 2012;54(5):416–22.

    Article  Google Scholar 

  10. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013 May 23;368(21):2004–13.

    CAS  Article  Google Scholar 

  11. Aikawa E, Nahrendorf M, Figueiredo JL, Swirski FK, Shtatland T, Kohler RH, et al. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation. 2007;116(24):2841–50.

    CAS  Article  Google Scholar 

  12. Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, Tseng PH, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49(18):1860–70.

    Article  Google Scholar 

  13. Mohlenkamp S, Lehmann N, Breuckmann F, Brocker-Preuss M, Nassenstein K, Halle M, et al. Running: the risk of coronary events : prevalence and prognostic relevance of coronary atherosclerosis in marathon runners. Eur Heart J. 2008;29(15):1903–10.

    Article  Google Scholar 

  14. Schwartz RS, Merkel-Kraus S, Schwartz JG, Wickstrom KK, Peichel G, Garberich RF, et al. Increased coronary artery plaque volume among male marathon runners. Mo Med. 2014;111(2):85–90.

    Google Scholar 

  15. Aengevaeren VL, Mosterd A, Braber TL, Prakken NHJ, Doevendans PA, Grobbee DE, et al. Relationship between lifelong exercise volume and coronary atherosclerosis in athletes. Circulation. 2017 Jul 11;136(2):138–48.

    CAS  Article  Google Scholar 

  16. • Merghani A, Maestrini V, Rosmini S, Cox AT, Dhutia H, Bastiaenan R, et al. Prevalence of subclinical coronary artery disease in masters endurance athletes with a low atherosclerotic risk profile. Circulation. 2017;136(2):126–37. In athletes with low-atherosclerotic risk, more athletes had CAC scores ≥  300 (11% versus 0, P = 0.009). Male athletes also had more stenoses ≥  50% (7.5% vs 0, P = 0.05) and plaques were more calcified. The predominantly calcific plaques in the athletes suggest a potentially different pathophysiological mechanisms for plaque formation in athletic versus sedentary men.

  17. Gabriel KP, Matthews KA, Perez A, Edmundowicz D, Kohl HW 3rd, Hawkins MS, et al. Self-reported and accelerometer-derived physical activity levels and coronary artery calcification progression in older women: results from the healthy women study. Menopause. 2013 Feb;20(2):152–61.

    Article  Google Scholar 

  18. Delaney JA, Jensky NE, Criqui MH, Whitt-Glover MC, Lima JA, Allison MA. The association between physical activity and both incident coronary artery calcification and ankle brachial index progression: the multi-ethnic study of atherosclerosis. Atherosclerosis. 2013 Oct;230(2):278–83.

    CAS  Article  Google Scholar 

  19. Otsuka F, Sakakura K, Yahagi K, Joner M, Virmani R. Has our understanding of calcification in human coronary atherosclerosis progressed? Arterioscler Thromb Vasc Biol. 2014;34(4):724–36.

    CAS  Article  Google Scholar 

  20. Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol. 2005 May 17;45(10):1563–9.

    CAS  Article  Google Scholar 

  21. Lin J, DeLuca JR, Lu MT, Ruehm SG, Dudum R, Choi B, et al. Extreme endurance exercise and progressive coronary artery disease. J Am Coll Cardiol. 2017;70(2):293–5.

    Article  Google Scholar 

  22. Williams PT, Thompson PD. Increased cardiovascular disease mortality associated with excessive exercise in heart attack survivors. Mayo Clin Proc. 2014 Sep;89(9):1187–94.

    Article  Google Scholar 

  23. Garatachea N, Santos-Lozano A, Sanchis-Gomar F, Fiuza-Luces C, Pareja-Galeano H, Emanuele E, et al. Elite athletes live longer than the general population: a meta-analysis. Mayo Clin Proc. 2014;89(9):1195–200.

    Article  Google Scholar 

  24. Radford NB, DeFina LF, Leonard D, Barlow CE, Willis BL, Gibbons LW, et al. Cardiorespiratory fitness, coronary artery calcium, and cardiovascular disease events in a cohort of generally healthy middle-age men: results from the Cooper Center longitudinal study. Circulation. 2018 May 1;137(18):1888–95.

    CAS  Article  Google Scholar 

  25. •• DeFina LF, Radford NB, Barlow CE, Willis BL, Leonard D, Haskell WL, et al. Association of all-cause and cardiovascular mortality with high levels of physical activity and concurrent coronary artery calcification. JAMA Cardiol. 2019. For any baseline age and CAC level, greater fitness was associated in a continuous fashion, with lower ASCVD events. Findings of this study supports the idea that high levels of physical activity are associated with prevalent CAC but this association does not seem to be linked to harm.

  26. Dollemore D. Aging hearts & arteries, a scientific quest; chapter-4, Blood vessels and aging: the rest of the journey. A publication of National Institute on Aging and National Institutes of Health.

  27. Maron BJ, Zipes DP, Kovacs RJ. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: preamble, principles, and general considerations: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2015 Dec 01;66(21):2343–9.

  28. Ballantyne CM, Raichlen JS, Nicholls SJ, Erbel R, Tardif JC, Brener SJ, et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008;117(19):2458–66.

    CAS  Article  Google Scholar 

  29. Hacker M, Becker C. The incremental value of coronary artery calcium scores to myocardial single photon emission computer tomography in risk assessment. J Nucl Cardiol. 2011;18(4):700–11 quiz 12-6.

    Article  Google Scholar 

  30. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56(25):e50–103.

    Article  Google Scholar 

  31. Berman DS, Wong ND, Gransar H, Miranda-Peats R, Dahlbeck J, Hayes SW, et al. Relationship between stress-induced myocardial ischemia and atherosclerosis measured by coronary calcium tomography. J Am Coll Cardiol. 2004;44(4):923–30.

    CAS  Article  Google Scholar 

  32. Budoff MJ, Raggi P, Beller GA, Berman DS, Druz RS, Malik S, et al. Noninvasive cardiovascular risk assessment of the asymptomatic diabetic patient: the Imaging Council of the American College of Cardiology. JACC Cardiovasc Imaging. 2016;9(2):176–92.

    Article  Google Scholar 

  33. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. 2018;10:CIR0000000000000625.

    Google Scholar 

  34. Manson JE, Allison MA, Carr JJ, Langer RD, Cochrane BB, Hendrix SL, et al. Calcium/vitamin D supplementation and coronary artery calcification in the Women’s Health Initiative. Menopause. 2010;17(4):683–91.

    PubMed  PubMed Central  Google Scholar 

  35. Samelson EJ, Booth SL, Fox CS, Tucker KL, Wang TJ, Hoffmann U, et al. Calcium intake is not associated with increased coronary artery calcification: the Framingham study. Am J Clin Nutr. 2012;96(6):1274–80.

    CAS  Article  Google Scholar 

  36. Noyes AM, Thompson PD. The effects of statins on exercise and physical activity. J Clin Lipidol. 2017;11(5):1134–44.

    Article  Google Scholar 

  37. Zhao XQ, Dong L, Hatsukami T, Phan BA, Chu B, Moore A, et al. MR imaging of carotid plaque composition during lipid-lowering therapy a prospective assessment of effect and time course. JACC Cardiovasc Imaging. 2011;4(9):977–86.

    Article  Google Scholar 

  38. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2):1–87.

    Article  Google Scholar 

  39. Juszczyk MA, Seip RL, Thompson PD. Decreasing LDL cholesterol and medication cost with every-other-day statin therapy. Prev Cardiol. 2005 Fall;8(4):197–9.

    Article  Google Scholar 

  40. Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol. 2008;101(12):1747–8.

    CAS  Article  Google Scholar 

  41. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism. 1997;46(10):1206–10.

    CAS  Article  Google Scholar 

  42. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431–43.

    CAS  Article  Google Scholar 

  43. Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalan R, Spinar J, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (improved reduction of outcomes: vytorin efficacy international trial). Circulation. 137(15):1571–82.

    CAS  Article  Google Scholar 

  44. Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. Jama. 2016;316(22):2373–84.

    CAS  Article  Google Scholar 

  45. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2018;376(18):1713–22.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Hartford Hospital, Hartford, CT, USA

    Antonio B. Fernandez MD, Waseem Chaudhry MD & Paul D. Thompson MD

  2. University of Connecticut School of Medicine, Farmington, CT, USA

    Antonio B. Fernandez MD, Waseem Chaudhry MD & Paul D. Thompson MD

  3. Athletes’ Heart Program, Hartford Hospital, 80 Seymour Street, Hartford, CT, 06102, USA

    Antonio B. Fernandez MD

Authors
  1. Antonio B. Fernandez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Waseem Chaudhry MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul D. Thompson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio B. Fernandez MD.

Ethics declarations

Conflict of Interest

Antonio B. Fernandez declares that he has no conflicts of interest. Waseem Chaudhry declares that he has no conflicts of interest.

Paul D. Thompson has received research support to his institution from Esperion, Amarin, and Amgen; has served as a consultant to Amgen, Regeneron, Sanolfi, Esperion, and Amarin; has received speaker honoraria from Amarin, Regeneron, Sanofi, Amgen, and Boehringer-Ingelheim, and owns stock in Abbvie, Abbott, CVS, J&J, Myocardia, Serapta, Boston Scientific, and Medtronic.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Sports Cardiology

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fernandez, A.B., Chaudhry, W. & Thompson, P.D. Coronary Atherosclerosis in Masters Athletes: Mechanisms and Implications for Cardiovascular Disease Risk. Curr Treat Options Cardio Med 21, 87 (2019). https://doi.org/10.1007/s11936-019-0798-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11936-019-0798-0

Keywords

  • Coronary artery disease
  • Masters athletes
  • Cholesterol
  • Atherosclerosis
  • Sudden cardiac death
  • Risk factors